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Table 3
Other secondary efficacy and safety assessments of the participants.
Assessment, n (%) Treatment group
Placebo (N=20) PANCREAZE® (N=20)
n (%) n (%)
EPI symptoms a
Any 11 (55) 4 (20)
Abdominal pain 6 (30) 3 (15)
Bloating 3 (15) 1 (5)
Diarrhea 4 (20) 0 (0)
Greasy stools 3 (15) 0 (0)
Vomiting 0 (0) 1 (5)
Stool category b
Abnormal stool 18 (90) 15 (75)
Hard 0 (0) 4 (20)
Soft 16 (80) 13 (65)
Watery or greasy 14 (70) 2 (10)
GAC score c
Excellent 0 (0) 4 (20)
Better 2 (10) 9 (45)
Same 11 (55) 7 (35)
Worse 7 (35) 0 (0)
Treatment-emergent adverse events
Any TEAE 12 (60) 8 (40)
Treatment-related TEAE 10 (50) 4 (20)
Most common TEAE d
Diarrhea 4 (20) 0 (0)
Abdominal pain 3 (15) 2 (10)
Abdominal pain upper 3 (15) 1 (5)
Flatulence 3 (15) 1 (5)
Abnormal feces 3 (15) 0 (0)
Fatigue 2 (10) 0 (0)
EPI: exocrine pancreatic insufficiency; GAC: global assessment of change;
TEAE: treatment-emergent adverse event.
a Number (percent) of patients with ≥1 EPI symptom during treatment.
b Reported at least one during treatment; hard, soft and watery or oily consid-
ered abnormal.
c Response at end of study.
d Occurring in ≥2 participants (≥10%) in either treatment group.
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